BRUSSELS, Belgium--(BUSINESS WIRE)--The European Myeloma Platform (EMP) welcomes new research published in this week’s New England Journal of Medicine which found that previously treated multiple myeloma patients who received REVLIMID with dexamethasone had an unprecedented nearly three year median survival rate – the longest median survival ever observed in Phase III trials of this patient group. In addition to increased overall survival, the findings from the two large, U.S. and international clinical trials found that patients who received the oral cancer therapy in combination with the steroid dexamethasone also had increased response rates, time-to-disease progression and duration of response compared to patients treated with the steroid alone.
